The not-so-dull results could be a problem for Chinese officials, as they believe in the effectiveness of vaccines made by Sinovac and Sinopharm, even if the vaccine is not regulatory approval and data from the late-stage trials is not yet public. But Beijing also gave it to thousands of Chinese people under its emergency use policy. It plans to vaccinate 50 million people by mid-next month.
State media in China posted in Brazilian news, the Global Times, the state’s nationalist tabloid, made headlines that the Sinovac vaccine “is 100 percent effective in preventing severe cases, reducing hospital admissions by 80 percent.”;
The new information may raise concerns among people around the world who are wary of vaccines made in China as the country has a history of vaccine quality scandals. A study from the Chinese University of Hong Kong found that only 37.2 percent of Hong Kong respondents were willing to get vaccinated.
Scientists have already raised questions about how efficacy data on China’s vaccines have been released. Indonesia said on Monday that an interim analysis showed CoronaVac had an efficiency rate of 65.3 percent last month.Turkey said it had an efficiency rate of 91.25 percent, but was based on preliminary results from small clinical trials.
The vaccine has been around for a long time in a political dimension in Brazil.President Jair Bolsonaro has spoken cynically about CoronaVac, which has fueled a growing anti-vaccination movement in a country where more deaths from Covid-19 are killed. The vaccine was sponsored by Sao Paulo Governor João Doria, who is expected to run for president in 2022 and is one of Bolsonaro’s loudest critics.
In Brazil, officials said the previously announced higher efficiency rates for CoronaVac were related to the proposed prevention of Covid-19 symptoms that were important enough to be treated. While officials confirmed last week that the vaccine provides complete protection for moderate to severe symptoms, they have not disclosed another group with the infection. “Very little” even after being vaccinated
Denise Garrett, a Brazilian-American epidemiologist and vaccine expert, said there was no reason to doubt the safety of CoronaVac, adding that the data presented so far suggest it would provide a satisfactory level of protection. Garrett said the vague and sometimes misleading nature of public disclosure of vaccines could shake people’s confidence and fuel the political battle over vaccines.